Valemetostat
- Generic Name
- Valemetostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34ClN3O4
- CAS Number
- 1809336-39-7
- Unique Ingredient Identifier
- 60RD0234VE
- Associated Conditions
- -
- Associated Therapies
- -
New anticancer drugs could significantly improve immunotherapy
EZH2 inhibitors enhance T cell-based immunotherapies, improving lymphoma treatment by reversing immunosuppression and boosting CAR-T cell efficacy, with promising preclinical results leading to ongoing clinical trials.
Lymphoma Immunotherapy Enhanced by Enzyme Inhibitor In Preclinical Model, Prompting ...
EZH2 inhibitors may enhance cancer immunotherapies, according to a Weill Cornell Medicine study. Combining T-cell-based immunotherapy with EZH2 inhibition was more effective at shrinking B-cell non-Hodgkin lymphomas (B-NHL) than immunotherapy alone. Pilot studies are underway to test this approach in lymphoma patients.
Valemetostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Valemetostat, a dual EZH1/EZH2 inhibitor, showed activity in relapsed/refractory peripheral T-cell lymphoma (PTCL) patients, with 44% objective response and manageable safety profile, in a phase II trial (VALENTINE-PTCL01).
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath